GlassScriptPhysician profile
Martin C Palmer
NPI 1124154448
$2,255.73
in general payments reported to CMS, 2019-2025
11 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.96 · 2022: $20.10 · 2023: $648 · 2024: $824 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $622.88 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| Tempus Ai, INC | $515.26 | 2024-2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $346.50 | 2023-2025 | Opdivo, Opdualag, Reblozyl |
| Eisai INC. | $278.44 | 2023-2025 | |
| Glaxosmithkline, LLC. | $243.47 | 2025 | Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $109.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $47.44 | 2025 | Keytruda, Keytruda Qlex |
| Sobi, INC | $41.32 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2025 | Fruzaqla |
| Abbvie INC. | $16.96 | 2021 | |
| Celgene Corporation | $13.57 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.